본문으로 건너뛰기
← 뒤로

Thermal field management in thyroid ablation for papillary thyroid carcinoma: Advancing precision and patient-centered care.

1/5 보강
World journal of radiology 2025 Vol.17(12) p. 114211
Retraction 확인
출처

Sathish S

📝 환자 설명용 한 줄

Thermal ablation has become an established minimally invasive alternative to surgery for papillary thyroid carcinoma, particularly in low-risk patients seeking effective treatment with reduced morbidi

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Sathish S (2025). Thermal field management in thyroid ablation for papillary thyroid carcinoma: Advancing precision and patient-centered care.. World journal of radiology, 17(12), 114211. https://doi.org/10.4329/wjr.v17.i12.114211
MLA Sathish S. "Thermal field management in thyroid ablation for papillary thyroid carcinoma: Advancing precision and patient-centered care.." World journal of radiology, vol. 17, no. 12, 2025, pp. 114211.
PMID 41480289

Abstract

Thermal ablation has become an established minimally invasive alternative to surgery for papillary thyroid carcinoma, particularly in low-risk patients seeking effective treatment with reduced morbidity. While clinical outcomes are favorable, wide variability in complication rates and patient-reported experiences persists across centers and operators, emphasizing the need for strategies that standardize safety and enhance quality of life. Cai now introduce thermal field management (TFM), a thoughtful approach that reframes thermal ablation from a purely technical procedure into a precision-guided, patient-centered intervention. By deliberately confining the ablation zone to protect surrounding tissues, TFM addresses complications such as voice change and pain, issues often overlooked in the pursuit of technical success. Their findings, showing reduced complications and improved patient comfort, highlight the value of integrating patient-reported outcomes into routine ablation practice. This places TFM within the broader trajectory of interventional oncology, where precision and patient-centeredness are becoming central goals. If validated in multicenter prospective studies, TFM could extend beyond thyroid cancer and inform the evolution of safer, standardized ablative therapies across multiple organ systems.